盐酸米托蒽醌膀胱内灌注预防膀胱癌术后复发的临床研究

Clinical evaluation of intravesical mitoxantrone to prevent relapse of bladder carcinoma.

目的 探讨盐酸米托蒽醌膀胱内灌注预防膀胱癌术后复发的临床疗效。方法 对16例膀胱癌患者手术后用米托蒽醌12 mg进行膀胱灌注,并随访4～19个月。结果 16例患者中有2例复发(12.5％),5例患者出现局部毒性反应,无全身毒性反应发生。结论 米托蒽醌是一种有效且耐受性较好的膀胱癌术后灌注药物。

Objective To evaluate the clinical curative effect of intravesical mitoxantione to prevent relapse of bladder carcinoma. Methods 16 cases of bladder carcinoma accepted the intravesical therapy with 12mg MTZ and were followed up for 4~ 19 months. Results 2 of 16 cases (12.5%) relapsed. 5 cases complained of local toxicity with no systemic toxicity happened. Conclusions MTZ is an effective and well - tolerated intravesical agent for prevention of relapse of post - operative bladder carcinoma.